Thanks to modern imaging and molecular characterization, neuroendocrine tumours can now be detected and classified in a much more targeted manner. New therapeutic procedures such as radioligand therapy and targeted drugs are increasingly enabling individualized treatment strategies.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
- ENETS
- ENETS-certified center Inselspital Bern
- gastroenteropancreatic NET peptide receptor radionuclide therapy (PRRT)
- heterogeneous group of neoplasms
- Hormone-producing cells of the neuroendocrine system
- NET histopathological and immunohistochemical examinations
- NET localizations of the gynaecological tract
- NET precise morphological and molecular characterization
- NET somatostatin receptor expression
- NET Somatostatin receptor PET/CT
- NET Tumor Biology
- NET University Hospital Zurich
- Neuroendocrine tumors (NET)
- SeqEveRIV study
- SwissNET
You May Also Like
- Cardiology and Nutrition
Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position
- Actinic keratoses
Targeted Treatment of Multiple AK Lesions—Balancing Efficacy and Convenience
- Obesity: A Multimodal and Interdisciplinary Approach
New Swiss Clinical Practice Guideline Provides Guidance
- cSCC: Personalizing Treatment Strategies and Follow-up Care Plans
Comprehensive risk stratification is no simple matter: what’s new?
- Baxdrostat – a new class of drugs for treating difficult-to-control hypertension
First Aldosterone Synthase Inhibitor Is Here
- Geriatric Small-Cell Lung Cancer
Therapeutic Challenges
- Chronic Pruritus in Renal, Hepatic, and Biliary Tract Diseases
Pooled Expertise for Targeted Evaluation and Treatment
- Advanced Thyroid Cancer